发明授权
US08530478B2 Piperazine derivatives used as CAV2.2 calcium channel modulators
有权
哌嗪衍生物用作CAV2.2钙通道调节剂
- 专利标题： Piperazine derivatives used as CAV2.2 calcium channel modulators
- 专利标题（中）： 哌嗪衍生物用作CAV2.2钙通道调节剂
-
申请号： US13054265申请日： 2009-07-15
-
公开(公告)号： US08530478B2公开(公告)日： 2013-09-10
- 发明人: Paul John Beswick , Alister Campbell , Andrew Peter Cridland , Robert James Gleave , Jag Paul Heer , Neville Hubert Nicholson , Lee William Page , Sadie Vile
- 申请人： Paul John Beswick , Alister Campbell , Andrew Peter Cridland , Robert James Gleave , Jag Paul Heer , Neville Hubert Nicholson , Lee William Page , Sadie Vile
- 申请人地址： GB London
- 专利权人： Convergence Pharmaceuticals Limited
- 当前专利权人： Convergence Pharmaceuticals Limited
- 当前专利权人地址： GB London
- 代理机构： Womble Carlyle Sandridge & Rice, LLP
- 优先权： GB0813142.7 20080717
- 国际申请： PCT/EP2009/059011 WO 20090715
- 国际公布： WO2010/007072 WO 20100121
- 主分类号： A61K31/496
- IPC分类号： A61K31/496 ; C07D401/06
摘要：
The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.